The GNG12 Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population with targeted disruption of the GNG12 gene in the human NCI-H1975 lung adenocarcinoma line. This loss-of-function model enables systematic analysis of gamma-12 subunit function in heterotrimeric G protein signaling, particularly within non-small cell lung cancer. The polyclonal format maintains cellular heterogeneity, supporting robust population-level studies of GNG12-dependent phenotypes.
The host cell line NCI-H1975 is a human lung adenocarcinoma model harboring EGFR mutations L858R and T790M, which drive oncogenic signaling and confer resistance to first-generation EGFR tyrosine kinase inhibitors. Derived from a metastatic non-small cell lung cancer, these cells exhibit aggressive proliferation and migration characteristics, making them a relevant system for investigating advanced lung cancer biology and treatment resistance mechanisms. This genetic background is ideal for exploring the interplay between GPCR and EGFR pathways in a therapeutically resistant setting.
GNG12 encodes the gamma-12 subunit of heterotrimeric G proteins, which couples GPCRs to intracellular effectors. Upstream receptors include CXCR4, LPAR, and S1PR, activated by chemokines, lysophosphatidic acid, and sphingosine-1-phosphate. Within the heterotrimer, GNG12 complexes with alpha subunits (GNAI2, GNAQ) and beta subunits (GNB1, GNB2) to regulate effectors such as adenylyl cyclase and phospholipase C beta (e.g., PLCB2). This triggers second messengers (cAMP, IP3, DAG, calcium), activating PKA, PKC, MAPK/ERK (MAPK1/3), and AKT cascades, ultimately modulating transcription factors CREB and AP-1 (FOS/JUN). These pathways control cell proliferation, migration, and survival.
In the NCI-H1975 EGFR-mutant background, GNG12 knockout may impair GPCR-driven MAPK/ERK and cAMP signaling, thus affecting cell proliferation, migration, and drug sensitivity. This model enables dissection of G??12-dependent pathways and their crosstalk with the EGFR axis, providing insight into adaptive resistance mechanisms where GPCRs bypass EGFR inhibition by reactivating downstream effectors. It is particularly suited to studying how GNG12 loss influences second messenger dynamics and transcription factor activity, offering a platform to evaluate the therapeutic targeting of G protein subunits in lung adenocarcinoma.
Typical uses include Western blotting and RT-qPCR for knockout validation and pathway analysis, RNA-seq for transcriptomic profiling, and functional assays measuring proliferation (MTT, colony formation), migration, and invasion. Drug sensitivity assays with EGFR inhibitors (gefitinib, osimertinib) and GPCR modulators, along with second messenger quantification (cAMP, calcium) and phospho-ERK/AKT analysis, further delineate GNG12 function. For technical inquiries, please contact Ascent Research.
